IL292372A - Compositions for drg-specific reduction of transgene expression - Google Patents
Compositions for drg-specific reduction of transgene expressionInfo
- Publication number
- IL292372A IL292372A IL292372A IL29237222A IL292372A IL 292372 A IL292372 A IL 292372A IL 292372 A IL292372 A IL 292372A IL 29237222 A IL29237222 A IL 29237222A IL 292372 A IL292372 A IL 292372A
- Authority
- IL
- Israel
- Prior art keywords
- sequence
- seq
- pct
- rule
- substitute sheet
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01076—L-Iduronidase (3.2.1.76)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- General Preparation And Processing Of Foods (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962924970P | 2019-10-23 | 2019-10-23 | |
| US201962934915P | 2019-11-13 | 2019-11-13 | |
| PCT/US2019/067872 WO2020132455A1 (en) | 2018-12-21 | 2019-12-20 | Compositions for drg-specific reduction of transgene expression |
| US202062972404P | 2020-02-10 | 2020-02-10 | |
| US202063005894P | 2020-04-06 | 2020-04-06 | |
| US202063023602P | 2020-05-12 | 2020-05-12 | |
| US202063038514P | 2020-06-12 | 2020-06-12 | |
| US202063043600P | 2020-06-24 | 2020-06-24 | |
| PCT/US2020/056881 WO2021081217A1 (en) | 2019-10-23 | 2020-10-22 | Compositions for drg-specific reduction of transgene expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL292372A true IL292372A (en) | 2022-06-01 |
Family
ID=75620360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL292372A IL292372A (en) | 2019-10-23 | 2020-10-22 | Compositions for drg-specific reduction of transgene expression |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220389457A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4048785A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7697943B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220105158A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020369570A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3155154A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL292372A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021081217A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL298138A (en) * | 2020-05-12 | 2023-01-01 | Univ Pennsylvania | Compositions for drg-specific reduction of transgene expression |
| US20230372539A1 (en) * | 2020-08-24 | 2023-11-23 | The Trustees Of The University Of Pennsylvania | Viral vectors encoding glp-1 receptor agonist fusions and uses thereof in treating metabolic diseases |
| KR20240100490A (ko) * | 2021-10-18 | 2024-07-01 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | Cdkl5 결핍 장애(cdd)의 치료에 유용한 조성물 |
| AU2022379625A1 (en) * | 2021-10-27 | 2024-05-16 | The University Of North Carolina At Chapel Hill | Aav-idua vector for treatment of mps i |
| US20260000790A1 (en) * | 2022-07-08 | 2026-01-01 | Ospedale San Raffaele S.R.L. | Transgene cassettes |
| CN116064593B (zh) * | 2023-02-09 | 2024-05-14 | 四川大学 | 一种毛白杨pgag基因及其应用 |
| WO2025188755A1 (en) * | 2024-03-04 | 2025-09-12 | Kate Therapeutics, Inc. | Adeno-associated virus compositions for the treatment of duchenne muscular dystrophy |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013151664A1 (en) * | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
| FR3004463A1 (fr) * | 2013-04-11 | 2014-10-17 | Genethon | Systeme d'expression pour une therapie genique selective |
| LT3137497T (lt) * | 2014-05-02 | 2021-07-26 | Genzyme Corporation | Aav vektoriai, skirti tinklainės ir cns genų terapijai |
| KR20220082100A (ko) * | 2015-05-15 | 2022-06-16 | 리젠츠 오브 더 유니버시티 오브 미네소타 | 중추 신경계로의 아데노-연관 치료적 전달 |
| MA43968A (fr) * | 2016-02-03 | 2018-12-12 | Univ Pennsylvania | Thérapie génique pour traiter la mucopolysaccharidose de type i |
| CN108697774A (zh) * | 2016-02-22 | 2018-10-23 | 北卡罗来纳大学教堂山分校 | 治疗mps i-相关失明的aav-idua载体 |
| CA3068328A1 (en) * | 2017-07-06 | 2019-01-10 | The Trustees Of The University Of Pennsylvania | Aav9-mediated gene therapy for treating mucopolysaccharidosis type i |
| DK3684423T5 (da) * | 2017-09-20 | 2024-08-26 | 4D Molecular Therapeutics Inc | Adeno-associerede virusvariantcapsider og fremgangsmåder til anvendelse deraf |
-
2020
- 2020-10-22 JP JP2022524118A patent/JP7697943B2/ja active Active
- 2020-10-22 CA CA3155154A patent/CA3155154A1/en active Pending
- 2020-10-22 AU AU2020369570A patent/AU2020369570A1/en active Pending
- 2020-10-22 EP EP20880317.1A patent/EP4048785A4/en active Pending
- 2020-10-22 IL IL292372A patent/IL292372A/en unknown
- 2020-10-22 US US17/770,137 patent/US20220389457A1/en active Pending
- 2020-10-22 WO PCT/US2020/056881 patent/WO2021081217A1/en not_active Ceased
- 2020-10-22 KR KR1020227016895A patent/KR20220105158A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021081217A1 (en) | 2021-04-29 |
| JP2022553406A (ja) | 2022-12-22 |
| EP4048785A1 (en) | 2022-08-31 |
| US20220389457A1 (en) | 2022-12-08 |
| CA3155154A1 (en) | 2021-04-29 |
| JP7697943B2 (ja) | 2025-06-24 |
| KR20220105158A (ko) | 2022-07-26 |
| AU2020369570A1 (en) | 2022-05-12 |
| EP4048785A4 (en) | 2024-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220389457A1 (en) | Compositions for drg-specific reduction of transgene expression | |
| JP7670759B2 (ja) | ムコ多糖症i型を治療するための遺伝子治療 | |
| US20260049335A1 (en) | Recombinant adeno-associated virus for treatment of grn-associated adult-onset neurodegeneration | |
| US20230304034A1 (en) | Compositions for drg-specific reduction of transgene expression | |
| SG11202105907QA (en) | Compositions for drg-specific reduction of transgene expression | |
| US20250295807A1 (en) | Compositions for drg-specific reduction of transgene expression | |
| US20230365955A1 (en) | Compositions and methods for treatment of fabry disease | |
| TW202227633A (zh) | 用於治療grn相關的成年發病神經退化之重組腺相關病毒 | |
| US20230414785A1 (en) | Compositions and uses thereof for treatment of angelman syndrome | |
| US20240115733A1 (en) | Compositions and methods for treatment of niemann pick type a disease | |
| US20240408157A1 (en) | Compositions and methods for treatment of fabry disease | |
| WO2025035143A1 (en) | Compositions and methods for treatment of spinal muscular atrophy |